BRAF and thyroid cancer: The aberrant stimulation of the mitogen-activated protein kinase (MAPK) pathway through alterations of BRAF (specifically the substitution of valine with glutamic acid at position 600 of the protein, the BRAF V600E mutation) leads to oncogenesis in up to 3% of people diagnosed with cancer, mainly in thyroid cancer and melanoma.